Hisun Biomaterials Reports 53.41% Revenue Growth as 3D Printing Demand Rises
Hisun Biomaterials reported RMB 953.34 million in revenue and RMB 27.45 million in attributable net profit for the first nine months of 2026, citing demand for 3D printing materials.
Chinese PLA producer Hisun Biomaterials (688203.SH) reported January–September 2026 revenue of RMB 953,335,942.58, up 53.41% year on year, and attributable net profit of RMB 27,446,953.50, up 459.49%. Third-quarter revenue alone was RMB 347,008,872.77, up 62.76%.
The company attributed growth partly to continued demand in 3D printing materials. This is management's explanation in an unaudited quarterly filing, which does not separately disclose 3D printing revenue; the profit increase is therefore not a direct measure of market-wide growth.
Key facts
- Jan–Sep revenue: RMB 953,335,942.58 (up 53.41%)
- Attributable net profit: RMB 27,446,953.50 (up 459.49%)
- Q3 revenue: RMB 347,008,872.77 (up 62.76%)
- Quarterly report is unaudited
Context
The filing signals FDM-related PLA demand at an upstream supplier, but more end-use disclosure is needed to quantify the contribution.
